Lantern Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LTRN research report →
About the company
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
- CEO
- Panna Sharma
- IPO
- 2020
- Employees
- 24
- HQ
- Dallas, TX, US
Price Chart
- Market Cap
- $50.65M
- P/E
- -2.74
- P/S
- 0.00
- P/B
- 12.97
- EV/EBITDA
- -2.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -198.35%
- ROIC
- -473.92%
- Revenue
- $0 · 0.00%
- Net Income
- $-17,119,438 · 17.62%
- EPS
- $-1.57 · 99.92%
- Op Income
- $-17,978,494
- FCF YoY
- 12.04%
- 52W High
- $5.74
- 52W Low
- $1.11
- 50D MA
- $3.20
- 200D MA
- $3.23
- Beta
- 2.33
- Avg Volume
- 264.16K
Get TickerSpark's AI analysis on LTRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Schalop Lee Troy | buy | 48,544 |
| May 12, 26 | Schalop Lee Troy | buy | 48,544 |
| May 12, 26 | KEYSER D JEFFREY | buy | 48,544 |
| May 12, 26 | KEYSER D JEFFREY | buy | 48,544 |
| Jan 9, 26 | KEYSER D JEFFREY | other | 28,844 |
| Jan 9, 26 | KEYSER D JEFFREY | other | 25,000 |
| Jan 9, 26 | Maccecchini Maria-Luisa | other | 25,000 |
| Jan 9, 26 | Maccecchini Maria-Luisa | other | 21,152 |
| Jan 9, 26 | Chandru Vijay | other | 25,000 |
| Jan 9, 26 | Chandru Vijay | other | 17,307 |
Our LTRN coverage
Recent articles, reports, and earnings notes.
No research on LTRN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LTRN report →Similar companies
Peers in the same neighborhood.